AI-generated research brief — verify at source
Apixaban Cuts Clinically Relevant Bleeding Risk by Half Versus Rivaroxaban in Acute VTE
In a randomized international trial of 2,760 patients with acute venous thromboembolism, apixaban was associated with approximately half the rate of clinically relevant bleeding compared with rivaroxaban over three months (3.3% vs. 7.1%; relative risk 0.46, 95% CI 0.33–0.65). This represents one of the first adequately powered head-to-head comparisons of these two widely used anticoagulants, providing direct evidence where observational data had previously dominated.
What Was Studied
Both apixaban and rivaroxaban are among the most frequently prescribed oral anticoagulants for treating acute venous thromboembolism (VTE), yet no large randomized trial had directly compared their bleeding profiles. This study sought to resolve persistent uncertainty about whether meaningful differences in bleeding risk exist between the two agents when used at their approved therapeutic doses.
How It Was Studied
The COBRRA trial was an international, prospective, randomized, open-label study with blinded endpoint adjudication — a design often referred to as PROBE. Eligible patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis were randomized 1:1 to receive either apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) or rivaroxaban (15 mg twice daily for 21 days, then 20 mg once daily) for a total treatment duration of three months. A total of 2,760 patients underwent randomization — 1,370 to apixaban and 1,390 to rivaroxaban — making this one of the largest head-to-head trials in this setting. The primary outcome was clinically relevant bleeding, defined as a composite of major bleeding and clinically relevant nonmajor bleeding per International Society on Thrombosis and Haemostasis criteria, assessed across the full three-month period.
What Was Observed
- Clinically relevant bleeding was roughly 54% lower with apixaban than rivaroxaban, occurring in 44 of 1,345 patients (3.3%) versus 96 of 1,355 patients (7.1%) — a statistically robust difference (relative risk 0.46, 95% CI 0.33–0.65; P<0.001), meaning the result is very unlikely to be due to chance.
- All-cause mortality was numerically lower in the apixaban group — 1 death (0.1%) versus 4 deaths (0.3%) in the rivaroxaban group — but the estimate was highly imprecise and not statistically conclusive (relative risk 0.25, 95% CI 0.03–2.26), meaning no reliable mortality difference can be inferred from this data alone.
- Serious adverse events unrelated to bleeding or VTE were balanced between groups, occurring in 36 patients (2.7%) in the apixaban arm and 30 patients (2.2%) in the rivaroxaban arm, suggesting the overall safety profiles beyond bleeding were comparable.
Why This Matters
Prior comparisons of apixaban and rivaroxaban in VTE treatment relied predominantly on observational or registry data, which are susceptible to confounding by indication and prescribing patterns. The COBRRA trial introduces randomized evidence at scale, directly testing whether the differing dosing regimens — particularly rivaroxaban’s extended twice-daily loading phase versus apixaban’s shorter one — translate into meaningful differences in patient safety outcomes. A near-halving of clinically relevant bleeding with apixaban is a substantial effect size that could reshape how researchers and guideline bodies weigh these agents against each other.
How to Read This Result
The open-label design introduces potential for differential outcome reporting or behavioral differences between groups, and it is important to note that the trial was not powered to detect differences in recurrent thromboembolism, which limits conclusions about comparative effectiveness beyond bleeding.
Limitations
The abstract does not explicitly report study limitations.